Submitted by Anonymous (not verified) on 13 November 2023 - 15:30
Human medicines European public assessment report (EPAR): Livmarli, Maralixibat chloride, Alagille Syndrome, Date of authorisation: 09/12/2022, Revision: 3, Status: Authorised
Source: